

the pending claims, as amended in light of the remarks presented herein, is respectfully requested.

Filed concurrently herewith is a Petition for Revival of an Application for Patent Abandoned Unintentionally Under 37 C.F.R. 1.137, along with the appropriate fee.

### AMENDMENTS

#### In the claims

Please cancel claims 1-30, 34-51, 53-56, 69 and 70, without prejudice.

Please add new claims 71-113, as follows:

Sub H 2  
71. A method to label cells with a product secreted by the cells, comprising culturing said cells under conditions wherein the product is secreted and bound to a capture moiety coupled to said cells wherein said capture moiety specifically binds the product, thereby labeling cells with said product, and wherein said product has been labeled with a label moiety.

72. A method to label cells with a product secreted by the cells, comprising the steps of:  
a) coupling said cells to a capture moiety;  
b) culturing said cells under conditions wherein the product is secreted and bound to said capture moiety, thereby labeling cells with a product secreted by said cells; and  
c) labeling said product with a label moiety.

73. The method of claim 71 wherein said capture moiety is coupled to said cells through an anchoring moiety.

74. The method of claim 72 wherein said capture moiety is coupled to said cells through an anchoring moiety.

75. The method of claim 71 wherein said cells remain viable during said method.

76. The method of claim 71 wherein the label moiety is an antibody specific for the product.

RECEIVED

AUG 25 2000

TECH CENTER 1500/2900

77. The method of claim 71 wherein the label moiety is fluorochromated.
78. The method of claim 71 wherein the label moiety is magnetizable.
79. The method of claim 78 wherein the label moiety comprises colloidal magnetic particles with a typical diameter of about 5 to 200 nm.
80. The method of claim 71 wherein the capture moiety is an antibody or an antigen-binding fragment thereof.
81. The method of claim 80 wherein the antibody or antigen binding fragment thereof is bispecific.
82. The method of claim 73 wherein the anchoring moiety is a lipid anchor.
83. The method of claim 73 wherein the anchoring moiety is an antibody, or an antigen-binding fragment thereof.
84. The method of claim 71 wherein said capture moiety is coupled to said cells through direct chemical coupling of the capture moiety to components on the cell surface, optionally through a linking moiety.
85. The method of claim 81 wherein the bispecific antibody specifically binds to the cell.
86. The method of claim 71 wherein said product includes cytokines, antibodies, hormones, enzymes or proteins.
87. The method of claim 86 wherein said cytokine includes IFN $\gamma$ , IL1, IL2, IL4, IL10, IL12, TGF $\beta$ , TNF, GMCSF, and SCF.

88. The method of claim 84 wherein said linking moiety includes branched polymers.

89. The method of claim 88 wherein said branched polymers includes modified dextran molecules, polyethylene glycol, polypropylene glycol, polyvinyl alcohol or polyvinylpyrrolidone.

90. The method of claim 71 wherein said cell comprises a cell surface marker.

91. The method of claim 90 wherein said cell surface marker includes CD3, CD4, CD8, CD19, CD20, CD14, CD16, CD15, CD45, class I MHC and Class II MHC molecules, CD34, CD38, CD33, CD56 T cell receptor, Fc receptor,  $\beta$ 2 microglobulin or immunoglobulin.

92. The method of claim 90 wherein said cell surface marker comprises a cell adhesion molecule.

93. A composition comprising cells labeled by the method of claim 71.

94. A composition comprising cells labeled by the method of claim 72.

Sub  
H3 95. A composition comprising cells labeled by a product secreted by said cells, wherein said cells are coupled to a capture moiety, wherein said capture moiety specifically binds the product secreted by said cell, and wherein said product is labeled with a label moiety.

96. The composition of claim 95 wherein said capture moiety is coupled to said cells through an anchoring moiety.

97. The composition of claim 95 wherein said capture moiety is an antibody or antigen-binding fragment thereof.

98. The composition of claim 97 wherein said antibody is bispecific.

99. The composition of claim 96 wherein said anchoring moiety is a lipid anchor.
100. The composition of claim 96 wherein said anchoring moiety is an antibody or an antigen-binding fragment thereof.
101. The composition according to claim 95 wherein the label moiety is an antibody specific for the product.
102. The composition according to claim 95 wherein the label moiety is fluorochromated.
103. The composition according to claim 95 wherein the label moiety is magnetizable.
104. The composition of claim 95 wherein said product includes cytokines, antibodies, hormones, enzymes or proteins.
105. The composition of claim 104 wherein said cytokine includes IFN $\gamma$ , IL1, IL2, IL4, IL10, IL12, TGF $\beta$ , TNF, GMCSF, and SCF.
106. The composition of claim 95 wherein said cell comprises a cell surface marker.
107. The composition of claim 106 wherein said cell surface marker includes CD3, CD4, CD8, CD19, CD20, CD14, CD16, CD15, CD45, class I MHC and Class II MHC molecules, CD34, CD38, CD33, CD56 T cell receptor, Fc receptor,  $\beta$ 2 microglobulin or immunoglobulin.
108. The composition of claim 106 wherein said cell surface marker comprises a cell adhesion molecule.
109. The composition of claim 95 wherein said capture moiety is coupled to said cells through direct chemical coupling of the capture moiety to components on the cell surface, optionally through a linking moiety.